

# Shifting Role of Oral Therapies in Psoriasis: Unmet Needs and Perspectives on Current and Emerging Therapies, and Evolving Treatment Sequencing Among Dermatologists



Authors: A. Stankus<sup>1</sup>, S. Chen<sup>1</sup>, S. Recchilungo<sup>1</sup>, C. Carpinella PhD<sup>1</sup>, J. Talia MD<sup>2</sup>

<sup>1</sup>Spherix Global Insights; <sup>2</sup>Mount Sinai Dermatology, Complex Medical Dermatology, Skin of Color Center

## Background:

Despite biologic adoption, dermatologists highlight unmet needs in psoriasis (PsO), including convenience, itch relief, and efficacy to treat high-impact areas. Independent tracking highlights shifting perceptions of current orals and growing enthusiasm for pipeline assets.

## Methods:

A 2025 cross-sectional survey of U.S. dermatologists (n=104) captured treatment sequencing, and perceptions of current and emerging oral therapies, following a comparable 2024 study.

## Objective:

To quantify dermatologist-reported changes in oral PsO therapy utilization, unmet needs, and pipeline opportunities.

## Results:







Deucravacitinib gained first-line traction, with dermatologists increasingly delaying biologic initiation.

- Compared to 2024, more physicians reported using deucravacitinib prior to biologics, rising from 55% to 66% (Figure 1). The average delay to biologic initiation also increased (≈14 to ≈17 weeks) (Figure 2).

While skin clearance remains the top priority, new analyses highlight:

- Itch relief, efficacy in high-impact areas, mechanism of action, and onset of action as critical differentiators for future orals (Figure 3).

Pipeline interest shifted year-over-year (Figure 4): oral IL-17 and aIL-23R mechanisms remained most valued (>83%) (Figure 5), but icotrokinra (oral aIL-23R) emerged as the leading candidate, with aIL-23R awareness surpassing IL-17 agents and >60% of dermatologists favoring icotrokinra for first-line use (Figure 6), while TYK2 inhibitors (envudeucitinib, zasocitinib) were increasingly viewed as later-line options.



## Conclusion:

Dermatologists report an expanding role for oral therapies in PsO (Figures 1–2, 6). Broader availability of effective oral agents is expected to further delay biologic initiation (Figures 1–2), representing a paradigm shift in PsO management.

## Acknowledgments:

Thank you to the Spherix Global Insights network of dermatologists and their patients.

## Disclosures:

Spherix Global Insights is an independent market intelligence and advisory firm that has not received any industry funding to conduct and report on this study. Dr. Jordan Talia has served as a consultant for AbbVie, Arcutis Biotherapeutics, Bristol-Meyers Squibb, Calliditas Therapeutics, Galderma, Johnson & Johnson, Leo Pharma, Novartis, Navigator Medicines, Primus Pharmaceuticals, Sanofi Genzyme, Stifel Financial, and UCB. He serves as an investigator for LEO Pharma, Privant Therapeutics and Sanofi. He is a shareholder of Nektar Therapeutics.